• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Predictors of Death in Rifampicin Resistant Tuberculosis Patients Treated with the Short Course in Conakry, Guinea.预测利福平耐药性结核病患者在科纳克里采用短程化疗治疗后的死亡因素。
Am J Trop Med Hyg. 2023 Nov 13;110(1):117-122. doi: 10.4269/ajtmh.23-0190. Print 2024 Jan 3.
2
Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.耐多药结核病的标准短程化疗:6个国家的治疗结果
JAMA. 2000 May 17;283(19):2537-45. doi: 10.1001/jama.283.19.2537.
3
Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success.南非开普敦凯伊利沙地区耐利福平结核病患者开始接受抗逆转录病毒治疗的时间:对死亡率和治疗成功率的影响
PLoS One. 2015 Nov 10;10(11):e0142873. doi: 10.1371/journal.pone.0142873. eCollection 2015.
4
Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.2012 - 2017年刚果民主共和国东部冲突后地区经Xpert MTB/RIF检测出的利福平耐药结核病的患病率、预测因素及成功治疗结果:一项全省范围的回顾性队列研究
Clin Infect Dis. 2019 Sep 27;69(8):1278-1287. doi: 10.1093/cid/ciy1105.
5
Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Southwestern Oromia, Ethiopia: ten-year retrospective analysis.在埃塞俄比亚奥罗米亚西南部,耐多药结核病患者的治疗结果和相关因素:十年回顾性分析。
BMC Infect Dis. 2024 Nov 14;24(1):1305. doi: 10.1186/s12879-024-10205-6.
6
Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda.卢旺达 HIV 合并感染患者中利福平耐药结核病死亡率的预测因素。
Am J Trop Med Hyg. 2021 May 17;105(1):47-53. doi: 10.4269/ajtmh.20-1361.
7
Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.中国湖南省耐多药和广泛耐药结核病患者的治疗结果
BMC Infect Dis. 2017 Aug 16;17(1):573. doi: 10.1186/s12879-017-2662-8.
8
Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.预测埃塞俄比亚奥罗米亚地区耐多药结核病患者不良治疗结局的时间的因素。
PLoS One. 2019 Oct 30;14(10):e0224025. doi: 10.1371/journal.pone.0224025. eCollection 2019.
9
[Treatment outcome, survival and their risk factors among new tuberculosis patients co-infected with HIV during the Ebola outbreak in Conakry].[科纳克里埃博拉疫情期间合并感染艾滋病毒的新结核病患者的治疗结果、生存率及其危险因素]
Rev Epidemiol Sante Publique. 2017 Nov;65(6):419-426. doi: 10.1016/j.respe.2017.05.011. Epub 2017 Oct 22.
10
National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in Ethiopia: a 10-year retrospective cohort study.国家治疗结局和埃塞俄比亚耐多药结核病死亡和治疗失败的预测因素:一项 10 年回顾性队列研究。
BMJ Open. 2021 Aug 10;11(8):e040862. doi: 10.1136/bmjopen-2020-040862.

本文引用的文献

1
Predictors of mortality and treatment success of multi-drug resistant and Rifampicin resistant tuberculosis in Zimbabwe: a retrospective cohort analysis of patients initiated on treatment during 2010 to 2015.津巴布韦耐多药和利福平耐药结核病患者死亡率和治疗成功率的预测因素:2010 年至 2015 年期间开始治疗的患者回顾性队列分析。
Pan Afr Med J. 2021 Jun 15;39:128. doi: 10.11604/pamj.2021.39.128.27726. eCollection 2021.
2
National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in Ethiopia: a 10-year retrospective cohort study.国家治疗结局和埃塞俄比亚耐多药结核病死亡和治疗失败的预测因素:一项 10 年回顾性队列研究。
BMJ Open. 2021 Aug 10;11(8):e040862. doi: 10.1136/bmjopen-2020-040862.
3
Predictors of mortality in patients with drug-resistant tuberculosis: A systematic review and meta-analysis.耐药结核病患者死亡的预测因素:系统评价和荟萃分析。
PLoS One. 2021 Jun 28;16(6):e0253848. doi: 10.1371/journal.pone.0253848. eCollection 2021.
4
Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda.卢旺达 HIV 合并感染患者中利福平耐药结核病死亡率的预测因素。
Am J Trop Med Hyg. 2021 May 17;105(1):47-53. doi: 10.4269/ajtmh.20-1361.
5
Survival analysis of patients with tuberculosis and risk factors for multidrug-resistant tuberculosis in Monrovia, Liberia.利比里亚蒙罗维亚的结核患者生存分析及耐多药结核的危险因素。
PLoS One. 2021 Apr 23;16(4):e0249474. doi: 10.1371/journal.pone.0249474. eCollection 2021.
6
Unfavorable outcomes to second-line tuberculosis therapy among HIV-infected versus HIV-uninfected patients in sub-Saharan Africa: A systematic review and meta-analysis.撒哈拉以南非洲地区感染 HIV 的与未感染 HIV 的结核病二线治疗不良结局:系统评价和荟萃分析。
PLoS One. 2020 Aug 14;15(8):e0237534. doi: 10.1371/journal.pone.0237534. eCollection 2020.
7
Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study.在几内亚,采用较短方案治疗耐多药结核病(MDR-TB)可获得更好的临床结局:一项回顾性队列研究。
PLoS One. 2020 Aug 10;15(8):e0237355. doi: 10.1371/journal.pone.0237355. eCollection 2020.
8
Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi.布隆迪耐利福平结核病患者短程治疗方案期间的不良事件病程
J Clin Med. 2020 Jun 16;9(6):1873. doi: 10.3390/jcm9061873.
9
Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries.九个非洲国家耐利福平结核病九个月治疗方案在治疗完成后长达24个月的转归
EClinicalMedicine. 2020 Feb 10;20:100268. doi: 10.1016/j.eclinm.2020.100268. eCollection 2020 Mar.
10
Survival of patients with multidrug-resistant tuberculosis in Central China: a retrospective cohort study.中国中部地区耐多药结核病患者的生存情况:一项回顾性队列研究。
Epidemiol Infect. 2020 Feb 19;148:e50. doi: 10.1017/S0950268820000485.

预测利福平耐药性结核病患者在科纳克里采用短程化疗治疗后的死亡因素。

Predictors of Death in Rifampicin Resistant Tuberculosis Patients Treated with the Short Course in Conakry, Guinea.

机构信息

Centre de Recherche et de Formation en Infectiologie de Guinée, Gamal Abdel Nasser University, Conakry, Republic of Guinea.

Département de Santé Publique, Gamal Abdel Nasser University, Conakry, Republic of Guinea.

出版信息

Am J Trop Med Hyg. 2023 Nov 13;110(1):117-122. doi: 10.4269/ajtmh.23-0190. Print 2024 Jan 3.

DOI:10.4269/ajtmh.23-0190
PMID:37956449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10793011/
Abstract

The emergence of rifampicin-resistant tuberculosis (RR-TB) is a major issue for TB control programs due to high risk of treatment failure and death. The objective of this study was to describe survival and to determine predictors of death in RR-TB patients treated with the short regimen (9-11 months) in the Conakry TB treatment centers. Sociodemographic, clinical, and survival data were collected prospectively between 2016 and 2021 on RR-TB patients in the Department of Pneumo-Phtisiology, the Carrière and the Tombolia TB centers. The Kaplan-Meier method was used to estimate the cumulative incidence of death of patients. The Cox regression model was used to identify the predictors independently associated with death. Of 869 patients, 164 (18.9%) patients died during treatment, 126 of them within 120 days of treatment initiation. The factors associated with death during treatment were as follows: patients treated in the Carrière TB center (adjusted hazard ratio [aHR] = 1.65; 95% CI: 1.06-2.59) and in the Department of Pneumo-Phtisiology (aHR = 3.26; 95% CI: 2.10-5.07), patients ≥ 55 years old (aHR = 4.80; 95% CI: 2.81-8.19), patients with no history of first-line TB treatment (aHR = 1.51; 95% CI: 1.05-2.16), and patients living with HIV (aHR = 2.81; 95% CI: 1.94-4.07). The results of this study can help the national TB control program to reconsider its therapeutic strategy to improve patient care in case of RR-TB. Large prospective clinical studies should be conducted to provide evidence of the impact of such factors like previous history of TB treatment and HIV infection on survival of RR-TB patients.

摘要

利福平耐药结核病(RR-TB)的出现是结核病控制项目的一个主要问题,因为其治疗失败和死亡的风险很高。本研究的目的是描述 RR-TB 患者的生存情况,并确定在科纳克里结核病治疗中心接受短程方案(9-11 个月)治疗的 RR-TB 患者死亡的预测因素。2016 年至 2021 年期间,在肺病学系、Carrière 和 Tombolia 结核病中心前瞻性收集了 RR-TB 患者的社会人口学、临床和生存数据。采用 Kaplan-Meier 法估计患者死亡的累积发生率。Cox 回归模型用于确定与死亡独立相关的预测因素。在 869 名患者中,有 164 名(18.9%)患者在治疗期间死亡,其中 126 名患者在治疗开始后 120 天内死亡。治疗期间死亡的相关因素如下:在 Carrière 结核病中心(调整后的危险比[aHR]=1.65;95%置信区间:1.06-2.59)和肺病学系(aHR=3.26;95%置信区间:2.10-5.07)接受治疗的患者、年龄≥55 岁的患者(aHR=4.80;95%置信区间:2.81-8.19)、无一线结核病治疗史的患者(aHR=1.51;95%置信区间:1.05-2.16)和 HIV 感染者(aHR=2.81;95%置信区间:1.94-4.07)。本研究的结果可以帮助国家结核病控制项目重新考虑其治疗策略,以改善 RR-TB 患者的护理。应开展大型前瞻性临床研究,以提供既往结核病治疗史和 HIV 感染等因素对 RR-TB 患者生存影响的证据。